PCSK9 inhibition to reduce cardiovascular events

New England Journal of Medicine

Volumn 376, Issue 18, 2017, Pages 1790-1791

  Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; PROPROTEIN CONVERTASE 9; TRIACYLGLYCEROL; SERINE PROTEINASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; EDITORIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; RISK REDUCTION; UNSTABLE ANGINA PECTORIS;

CHOLESTEROL, LDL; HUMANS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 85017617053     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1703138     Document Type: Editorial

References (10)

1. Marais DA Blom DJ Petrides F Goufic Y Lambert G. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012;23:511-7.
2. Kwakernaak AJ, Lambert G, Dullaart RP. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. Clin Biochem 2014; 47: 679-82.
3. Chan DC, Lambert G, Barrett PH, Rye KA, Ooi EM, Watts GF. Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism? Clin Chem 2009; 55: 2049-52.
4. Watts GF, Chan DC, Dent R, et al. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation 2017; 135: 338-51.
5. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9.
6. Desai NR, Giugliano RP, Wasserman SM, et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol 2017 January 25 (Epub ahead of print).
7. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
8. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22.
9. Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J 2016; 37: 2981-9.
10. Landmesser U, John Chapman M, Farnier M, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016 October 27 (Epub ahead of print).